The `collateral benefits` of noninsulin therapies for Type 2 diabetes

Author： Roe Erin D Pon Natalie C Hollander Priscilla Raskin Philip

ISSN： 1758-1907

Source： Diabetes Management, Vol.3, Iss.2, 2013-03, pp. : 145-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Treatment of Type 2 Diabetes Mellitus in Youth: Which Therapies?

By Miller Jennifer L. Silverstein Janet H.

Treatments in Endocrinology, Vol. 5, Iss. 4, 2006-01 ,pp. : 201-210

Adis International

Access to resources Recommend Favorite

Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance

Current Diabetes Reviews, Vol. 9, Iss. 5, 2013-09 ,pp. : 412-417

Bentham Science Publishers

Access to resources Recommend Favorite

A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39 845 patients

By Esposito Katherine Chiodini Paolo Ceriello Antonio Giugliano Dario

Acta Diabetologica, Vol. 51, Iss. 2, 2014-04 ,pp. : 305-311

Springer Publishing Company

Access to resources Recommend Favorite

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors

Current Diabetes Reviews, Vol. 4, Iss. 2, 2008-05 ,pp. : 101-109

Bentham Science Publishers

Access to resources Recommend Favorite